VLA-4/CD49d downregulated on primed T lymphocytes during interferon-β therapy in multiple sclerosis

Journal of Neuroimmunology

Volumn 111, Issue 1-2, 2000, Pages 186-194

  Muraro, P A ^a,b   Leist, T ^a   Bielekova, B ^a   McFarland, H F ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

Adhesion molecules; Interferon ; Multiple sclerosis; T lymphocytes; VLA 4

Indexed keywords

CD27 ANTIGEN; CD4 ANTIGEN; CD49D; CD8 ANTIGEN; CELL ADHESION MOLECULE; CELL SURFACE MARKER; INTEGRIN; INTERFERON BETA SERINE; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CELL SURFACE; CLINICAL ARTICLE; ENCEPHALITIS; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

ADJUVANTS, IMMUNOLOGIC; ANTIGENS, CD; ANTIGENS, CD27; ANTIGENS, CD29; ANTIGENS, CD4; ANTIGENS, CD45; ANTIGENS, CD58; ANTIGENS, CD8; BIOLOGICAL MARKERS; DOWN-REGULATION; FEMALE; FLOW CYTOMETRY; HLA-DR ANTIGENS; HUMAN; IMMUNOLOGIC MEMORY; INTEGRIN ALPHA4; INTEGRIN ALPHA4BETA1; INTEGRINS; INTERCELLULAR ADHESION MOLECULE-1; INTERFERON-BETA; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECEPTORS, LYMPHOCYTE HOMING; T-LYMPHOCYTES;

EID: 0034333256     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(00)00362-3     Document Type: Article

References (25)

1. Heterogeneity of the circulating human CD4+ T cell population: further Evidence that the CD4+CD45RA-CD27- T cell subset contains specialized primed T cells
2. VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta
3. The adhesion molecule and cytokine profile of multiple sclerosis lesions
4. Microglial production of TNF-a is induced by activated T lymphocytes: involvement of VLA-4 and inhibition by interferon β-1b
5. The CD27- subset of peripheral blood memory CD4+ lymphocytes contains functionally differentiated T lymphocytes that develop by persistent antigenic stimulation in vivo
6. Placebo-controlled multicentre randomised trial of interferon b-1b in treatment of secondary progressive multiple sclerosis
7. Phenotypic and functional separation of memory and effector human CD8(+) T cells
8. Regulation of CD27 expression on subsets of mature T-lymphocytes
9. Differential expression of VLA-alpha 4 and VLA-beta 1 discriminates multiple subsets of CD4+CD45R0+ 'memory' T cells
10. Integrins: versatility, modulation, and signaling in cell adhesion
11. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)
12. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-β 1a in relapsing-remitting multiple sclerosis
13. Regulatory mechanisms in leukocyte adhesion: flexible receptors for sophisticated travelers
14. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group
15. Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis
16. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis
17. Differential expression of integrins alpha 6 and alpha 4 determines pathways in human peripheral CD4+ T cell differentiation
18. Lymphocyte interactions with endothelial cells
19. The effect of interferon-β on blood-brain-barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis
20. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
21. The effect of anti-a4 integrin antibody on brain lesion activity in MS
22. T lymphocye adhesion to human brain pericytes is mediated via very late antigen-4/vascular cell adhesion molecule-1 interactions
23. Interferon beta in the treatment of multiple sclerosis
24. Prevention of experimental autoimmune encephalomyelitis by antibodies against a4b1 integrin